ALBI (Albumin-Bilirubin) Grade for Hepatocellular Carcinoma (HCC)
ورودیهای بالینی بیمار
حداقل ۱۰ — حداکثر ۶۰ • واحد: g/L
حداقل ۱ — حداکثر ۱۰۰۰ • واحد: μmol/L
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Grade 1-10–-2.6
- Grade 2-2.6–-1.39
- Grade 3-1.39–10
The ALBI (Albumin-Bilirubin) Grade for Hepatocellular Carcinoma (HCC) calculates predicting survival in hepatocellular carcinoma patients based on objective measures of liver function (albumin and bilirubin). Key inputs include albumin. Scores guide adjusting systemic antineoplastic regimens, planning supportive palliative measures, or targeted monitoring. Routine clinical application promotes standardized evidence-based patient management.
Clinical Guidelines & Evidence
Predicts survival in hepatocellular carcinoma patients based on objective measures of liver function (albumin and bilirubin)
Clinical Indication
The ALBI (Albumin-Bilirubin) Grade for Hepatocellular Carcinoma (HCC) is indicated for bedside clinical practice to support Predicts survival in hepatocellular carcinoma patients based on objective measures of liver function (albumin and bilirubin). It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.
Limitations & Contraindications
Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care.
Clinical Pearls & Action Plan
Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival. Guideline pearl: Useful for treatment selection and prognostication.
ALBI = (log10 bilirubin × 0.66) + (albumin × -0.085), where bilirubin is in μmol/L and albumin in g/L
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| albumin | float | Yes | Serum albumin level in g/L(g/L) |
| bilirubin | float | Yes | Serum bilirubin level in μmol/L(μmol/L) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| -10–-2.6 | Grade 1 | Best liver function |
| -2.6–-1.39 | Grade 2 | Intermediate liver function |
| -1.39–10 | Grade 3 | Poor liver function |
Evidence-Based References (EBM)
- Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33(6):550-8.
- Hiraoka A, Michitaka K, Kumada T, et al. Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function. Liver Cancer. 2017;6(4):325-336.
- Chen B, Lin S. Albumin-bilirubin (ALBI) score at admission predicts possible outcomes in patients with acute-on-chronic liver failure. Medicine (Baltimore). 2017;96(24):e7142.